Immunotherapeutic interventions of Triple Negative Breast Cancer
Abstract Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast cancer that lacks the expression of oestrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. Although TNBC is sensitive to chemotherapy, the overall outcomes of TNBC are worse t...
Main Authors: | Zehuan Li, Yiran Qiu, Weiqi Lu, Ying Jiang, Jin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-018-1514-7 |
Similar Items
-
New chemotherapy options for triple-negative breast cancer (review of literature)
by: M A Sekundova, et al.
Published: (2014-03-01) -
Immunotherapy Treatment for Triple Negative Breast Cancer
by: Elizabeth R. Berger, et al.
Published: (2021-08-01) -
Progress of Immunotherapy and Its Application in Triple Negative Breast Cancer
by: ZHENG Hongmei, et al.
Published: (2020-11-01) -
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
by: Inna P. Ganshina, et al.
Published: (2021-02-01) -
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
by: Mehanna J, et al.
Published: (2019-07-01)